CSIMarket
 
Chemomab Therapeutics Ltd   (CMMB)
Other Ticker:  
 
 
Price: $0.6600 $-0.03 -3.650%
Day's High: $0.6698 Week Perf: -1.49 %
Day's Low: $ 0.63 30 Day Perf: 14.38 %
Volume (M): 62 52 Wk High: $ 1.89
Volume (M$): $ 41 52 Wk Avg: $1.08
Open: $0.67 52 Wk Low: $0.42



 Market Capitalization (Millions $) 146
 Shares Outstanding (Millions) 221
 Employees 9
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 31
 Cash Flow (TTM) (Millions $) 7
 Capital Exp. (TTM) (Millions $) 0

Chemomab Therapeutics Ltd
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company that is committed to developing novel and effective solutions for inflammatory and fibrotic diseases. The company was founded in 2014 and is headquartered in Israel. Its core platform technology is based on the development of highly selective monoclonal antibodies, which have the potential to create breakthrough therapies for a wide range of diseases.

Chemomab Therapeutics' lead product candidate, CM-101, is a first-in-class monoclonal antibody targeting the CCL24 protein, which is a key player in the inflammatory process. The antibody has shown highly promising results in preclinical and early clinical trials, demonstrating its potential to treat a wide range of inflammatory diseases, including fibrosis, arthritis, asthma, and allergies.

The company's development strategy is focused on leveraging its core technology platform to develop a suite of highly selective monoclonal antibodies targeting various inflammation and fibrosis pathways. This approach allows the company to identify the best target proteins for a particular disease and develop highly effective and safe therapies with reduced side effects.

Chemomab Therapeutics has a highly experienced management team with a strong track record of developing and commercializing novel therapies. The company is backed by a group of prominent investors and has partnerships with several leading pharmaceutical companies.

In summary, Chemomab Therapeutics Ltd is a highly innovative biotechnology company focused on developing novel and effective solutions for inflammatory and fibrotic diseases. The company's proprietary technology platform and highly selective monoclonal antibodies have the potential to create life-changing therapies for patients suffering from these debilitating conditions.


   Company Address: Kiryat Atidim Tel Aviv 6158002
   Company Phone Number: 77-331-0156   Stock Exchange / Ticker: NASDAQ CMMB
   CMMB is expected to report next financial results on March 19, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Chemomab Therapeutics Ltd

Chemomab Therapeutics Ltd Surges with 77.93% Return on Equity in Q1 2023, Outperforming Industry Leaders

Chemomab Therapeutics Ltd Delivers Impressive Q1 2023 Results, ROE Increases to 77.93%
Chemomab Therapeutics Ltd, a leading pharmaceutical company, has announced its first quarter 2023 financial results, showcasing an incredible return on equity (ROE) of 77.93%. This figure is significantly above CMMB's average ROE of 2.42%, demonstrating the company's commitment to generating better profits for its investors.
The impressive ROE is a substantial improvement from 58.23% in the previous quarter, driven by growth in net income. In the major pharmaceutical preparations industry, Chemomab Therapeutics Ltd ranks fifth in terms of ROE, trailing only four other companies. However, the company's overall ROE ranking has shown strong growth, jumping to 74 in the present quarter compared to its previous ranking of 182 in Q4 2022.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com